RxDoctor Payments Data

Aditya Mandawat, MD

Interventional Cardiology · Chattanooga, TNNPI 1528351632

Payments from drug & device makers

$3,366in general payments, 2019–2025

Across 179 payments — averaging $18.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$1K
  • Abiomed$360
  • Abbott$349
  • Getinge USA Sales, LLC$229
  • Novartis$221
  • Cardiovascular Systems Inc.$129
  • plus $583 from 15 others

What the payments were for

  • Food & beverage$3,366100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,366 in reported general payments places this provider in the 20th percentile of 207 interventional cardiology providers in Tennessee.

See all interventional cardiology providers in Tennessee

Medicare billing

Part B allowed, 2024
$176,263
Medicare patients
1,781
Services billed
3,536

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban628$667,553
EntrestoSacubitril/Valsartan240$283,500
JardianceEmpagliflozin258$247,589
XareltoRivaroxaban164$172,418
Repatha SureclickEvolocumab81$95,415
FarxigaDapagliflozin Propanediol23$34,743
BrilintaTicagrelor25$16,479
Dabigatran EtexilateDabigatran Etexilate Mesylate57$12,536
Ezetimibe348$12,064
Praluent PenAlirocumab11$11,681
Metoprolol Succinate947$11,489
Atorvastatin Calcium637$9,352
Rosuvastatin Calcium619$7,708
ClopidogrelClopidogrel Bisulfate558$7,296
Varenicline Tartrate26$5,763

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$31$667,553628 claims
NovartisEntresto$221$283,500240 claims
Johnson & JohnsonXarelto$16$172,418164 claims
AstraZenecaFarxiga, Brilinta$24$51,22248 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 207 interventional cardiology providers in Tennessee.

Other interventional cardiology in Chattanooga

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →